Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1735-1746

  Rajasagi, Naveen K ^a   Reddy, Pradeep B J ^a   Suryawanshi, Amol ^a   Mulik, Sachin ^a   Gjorstrup, Per ^b   Rouse, Barry T ^a,c  

^a UNIVERSITY OF TENNESSEE   (United States)

^b Resolvyx Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CXCL1 CHEMOKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; RESOLVIN E1; RX 10005; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORNEA; CORNEA NEOVASCULARIZATION; CYTOKINE PRODUCTION; FEMALE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STROMAL KERATITIS; TH1 CELL; TH17 CELL; VIRAL EYE INFECTION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CORNEA; DISEASE MODELS, ANIMAL; EICOSAPENTAENOIC ACID; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; INFLAMMATION MEDIATORS; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; NEUTROPHILS;

EID: 79251535612     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003456     Document Type: Article

References (41)

1. Liesegang, T. J. 2001. Herpes simplex virus epidemiology and ocular importance. Cornea 20: 1-13. (Pubitemid 32038147)
2. Colin, J. 2007. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 1: 441-453.
3. Deshpande, S., K. Banerjee, P. S. Biswas, and B. T. Rouse. 2004. Herpetic eye disease: immunopathogenesis and therapeutic measures. Expert Rev. Mol. Med. 6: 1-14.
4. Knickelbein, J. E., R. L. Hendricks, and P. Charukamnoetkanok. 2009. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv. Ophthalmol. 54: 226-234.
5. McGhee, C. N., S. Dean, and H. Danesh-Meyer. 2002. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 25: 33-55.
6. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
7. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192: 1197-1204.
8. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
9. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102: 7671-7676.
10. Vassiliou, E. K., O. M. Kesler, J. H. Tadros, and D. Ganea. 2008. Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J. Immunol. 181: 4534-4544.
11. Bannenberg, G., and C. N. Serhan. 2010. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801: 1260-1273.
12. Zhang, F., H. Yang, Z. Pan, Z. Wang, J. M. Wolosin, P. Gjorstrup, and P. S. Reinach. 2010. Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation. Invest. Ophthalmol. Vis. Sci. 51: 5601-5609.
13. Keyes, K. T., Y. Ye, Y. Lin, C. Zhang, J. R. Perez-Polo, P. Gjorstrup, and Y. Birnbaum. 2010. Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 299: H153-H164.
14. Haworth, O., M. Cernadas, R. Yang, C. N. Serhan, and B. D. Levy. 2008. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9: 873-879.
15. Ishida, T., M. Yoshida, M. Arita, Y. Nishitani, S. Nishiumi, A. Masuda, S. Mizuno, T. Takagawa, Y. Morita, H. Kutsumi, et al. 2010. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16: 87-95.
16. Hasturk, H., A. Kantarci, E. Goguet-Surmenian, A. Blackwood, C. Andry, C. N. Serhan, and T. E. Van Dyke. 2007. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179: 7021-7029.
17. Connor, K. M., J. P. SanGiovanni, C. Lofqvist, C. M. Aderman, J. Chen, A. Higuchi, S. Hong, E. A. Pravda, S. Majchrzak, D. Carper, et al. 2007. Increased dietary intake of v-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13: 868-873.
18. Li, N., J. He, C. E. Schwartz, P. Gjorstrup, and H. E. Bazan. 2010. Resolvin e1 improves tear production and decreases inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther. 26: 431-439.
19. Seki, H., K. Fukunaga, M. Arita, H. Arai, H. Nakanishi, R. Taguchi, T. Miyasho, R. Takamiya, K. Asano, A. Ishizaka, et al. 2010. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184: 836-843.
20. Deshpande, S. P., M. Zheng, S. Lee, and B. T. Rouse. 2002. Mechanisms of pathogenesis in herpetic immunoinflammatory ocular lesions. Vet. Microbiol. 86: 17-26.
21. Niemialtowski, M. G., and B. T. Rouse. 1992. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis. J. Immunol. 149: 3035-3039.
22. Hendricks, R. L., and T. M. Tumpey. 1990. Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology. Invest. Ophthalmol. Vis. Sci. 31: 1929-1939.
23. Aoki, H., T. Hisada, T. Ishizuka, M. Utsugi, A. Ono, Y. Koga, N. Sunaga, T. Nakakura, F. Okajima, K. Dobashi, and M. Mori. 2010. Protective effect of resolvin E1 on the development of asthmatic airway inflammation. Biochem. Biophys. Res. Commun. 400: 128-133.
24. Campbell, E. L., C. F. MacManus, D. J. Kominsky, S. Keely, L. E. Glover, B. E. Bowers, M. Scully, W. J. Bruyninckx, and S. P. Colgan. 2010. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc. Natl. Acad. Sci. USA 107: 14298-14303.
25. Kim, B., P. P. Sarangi, Y. Lee, S. Deshpande Kaistha, S. Lee, and B. T. Rouse. 2006. Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation. J. Leukoc. Biol. 80: 1405-1415.
26. Thomas, J., S. Gangappa, S. Kanangat, and B. T. Rouse. 1997. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J. Immunol. 158: 1383-1391.
27. Biswas, P. S., K. Banerjee, P. R. Kinchington, and B. T. Rouse. 2006. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp. Eye Res. 82: 46-54.
28. Lee, S., M. Zheng, B. Kim, and B. T. Rouse. 2002. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J. Clin. Invest. 110: 1105-1111.
29. Sarangi, P. P., S. Sehrawat, S. Suvas, and B. T. Rouse. 2008. IL-10 and natural regulatory T cells: two independent anti-inflammatory mechanisms in herpes simplex virus-induced ocular immunopathology. J. Immunol. 180: 6297-6306.
30. Tumpey, T. M., V. M. Elner, S. H. Chen, J. E. Oakes, and R. N. Lausch. 1994. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J. Immunol. 153: 2258-2265.
31. Schwab, J. M. N., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
32. Navarro-Xavier, R. A., J. Newson, V. L. F. Silveira, S. N. Farrow, D.W. Gilroy, and J. Bystrom. 2010. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184: 1516-1525.
33. Zheng, M., S. Deshpande, S. Lee, N. Ferrara, and B. T. Rouse. 2001. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 75: 9828-9835.
34. Biswas, P. S., and B. T. Rouse. 2005. Early events in HSV keratitis - setting the stage for a blinding disease. Microbes Infect. 7: 799-810.
35. Jin, Y., M. Arita, Q. Zhang, D. R. Saban, S. K. Chauhan, N. Chiang, C. N. Serhan, and R. Dana. 2009. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 50: 4743-4752.
36. Steinman, L. 2007. A brief history of T(H)17, the first major revision in the T(H) 1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139-145.
37. Maertzdorf, J., A. D. Osterhaus, G. M. Verjans, and M. G. M. Verjans. 2002. IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J. Immunol. 169: 5897-5903.
38. Couper, K. N., D. G. Blount, and E. M. Riley. 2008. IL-10: the master regulator of immunity to infection. J. Immunol. 180: 5771-5777.
39. Bystrom, J., I. Evans, J. Newson, M. Stables, I. Toor, N. van Rooijen, M. Crawford, P. Colville-Nash, S. Farrow, and D. W. Gilroy. 2008. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112: 4117-4127.
40. Zheng, M., M. A. Schwarz, S. Lee, U. Kumaraguru, and B. T. Rouse. 2001. Control of stromal keratitis by inhibition of neovascularization. Am. J. Pathol. 159: 1021-1029.
41. Penn, J. S., A. Madan, R. B. Caldwell, M. Bartoli, R. W. Caldwell, and M. E. Hartnett. 2008. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 27: 331-371.